Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink